NEATO-ROBOTICS
4.9.2020 13:32:20 CEST | Business Wire | Pressemeddelelse
Neato Robotics, en førende leverandør af intelligente robotstøvsugere til hjemmet, har i dag annonceret lanceringen af de nye modeller i deres kvalitetsserie – Neato D10, D9 og D8 – på IFA Berlin 2020. Neato-robotstøvsugere er den ultimative partner inden for rengøring, idet de har den bedste teknologi i klassen, nem indstilling og hardware, der er skabt til at holde.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20200904005047/da/
"Vi har kombineret Neatos 15 års erfaring i branchen med kundefeedback og de seneste nyskabelser inden for robotteknologi og kunstig intelligens, og vi er glade for at kunne introducere disse fantastiske nye produkter – vores bedste indtil nu – for hele verden. Neatos nye serie af intelligente robotstøvsugere er unik i design og teknologi, med en førsteklasses brugeroplevelse og en ny MyNeato-app, som viser vores forpligtelse til at gøre hverdagen nemmere med robotteknologi", siger Neatos CEO, Thomas Nedder.
De nye Neato-robotstøvsugere har kvalitet og brugeroplevelse, der er bedst i deres klasse, samtidig med, at deres D-formede design, som er det første af sin art i branchen, har fået et løft. Neato-ejere kan nå fra hjørne til hjørne og fra kant til kant og få en mere komplet rengøring ved at bruge den bredeste børste og den største støvbeholder på markedet. Neato har det første originale HEPA-filter, og Neato D10 opfanger op til 99,97 % allergener og partikler såsom støv og skæl helt ned til 0,3 my. Det har aldrig været nemmere at indstille en Neato, med en Bluetooth-aktiveret tilslutning til wi-fi og effektiviseret sekstrins-proces på vores nye MyNeato-app – den korteste indstillingsproces i branchen – for straks at komme i gang med rengøringen.
Neato D10
Med en køretid på op til 150 minutter, et originalt HEPA-filter til at opfange op til 99,97 % allergener så små som 0,3 my samt den seneste LaserSmartTM LIDAR-baserede teknologi, er Neato D10 ultraydeevnen til den ultimative rengøring.
Neato D9
Neato D9 gør det beskidte arbejde for dig. Med et ultraydende filter i HEPA-stil, der opfanger 99,5 % støv og allergener, en køretid på op til 120 minutter samt Neatos signatur-teknologi, LaserSmartTM , gør Neato rent når og hvor du ønsker det, også når det er mørkt.
Neato D8
Neato D8 leveres med branchens første signaturkvalitet og -teknologi, som du er vant til at forvente fra Neato – som fx den største støvbeholder, ekstra bred børste og den seneste LaserSmartTM -teknologi – med en bedre brugeroplevelse, en køretid på op til 90 minutter og forbedret effektiv rengøring.
Den nye produktserie vil være tilgængelig i efteråret 2020 hos vores detailhandlere i hele Nordamerika, Europa og Japan, samt i USA på NeatoRobotics.com .
Om Neato
Neato Robotics udvikler intelligente robotter til hjemmet for at gøre livet nemmere for folk og løse reelle problemer. Neato er engageret i at skabe en ægte brugerdefineret rengøringsoplevelse, hvor vi sikrer, at robotterne udvikles og tilpasses til forbrugeren. Neato driver innovation med intelligent LaserSmartTM LIDAR-baseret navigation, kortlægning, smart hjemmeopkobling og uovertruffen rengøringsteknologi. Få mere at vide på www.neatorobotics.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200904005047/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release
Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
